ENDOCYTE INC
ENDOCYTE INC (ECYT): 7 pipeline candidates · ~64 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
64.2 months
D/E 0.02 · 0% dilution
Lead: Phase 3
7 candidates
N/A
N/A
A transparent, data-derived signal for ENDOCYTE INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$67.3M
Quarterly Burn
$15.5M
Runway
64.2 mo
Revenue
$86K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| 177lu-psma-617 | Phase 3 |
| ec1169 | Phase 1 |
| ec1456 | Phase 1 |
| ec17 | Preclinical |
| ec2319 | Preclinical |
| ec2629 | Preclinical |
| vintafolide | Phase 2 |
Frequently asked questions
How many drug candidates are in ENDOCYTE INC's pipeline?
ENDOCYTE INC (ECYT) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ENDOCYTE INC's lead drug candidate?
ENDOCYTE INC's most advanced tracked candidate is 177lu-psma-617 (Phase 3) for progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
What is ENDOCYTE INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ENDOCYTE INC has approximately 64.2 months of cash runway.
Who is the CEO of ENDOCYTE INC?
Contents Endocyte is the chief executive officer of ENDOCYTE INC (ECYT).
Get the full picture on ENDOCYTE INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.